Nov 3, 4:09 PM ET
QuidelOrtho reported third-quarter 2026 revenue of $619 million, down 12% from the prior year, and a GAAP net loss of $54 million, or $0.78 per diluted share. The company lowered its top-end 2026 guidance for adjusted diluted EPS to $0.65 to $0.70 from $0.65 to $0.90, and launched a restructuring program it expects to save over $80 million a year in 2027, with $30 million to $35 million in one-time charges in the fourth quarter of 2026.
- Q3 2026 revenue $619 million, down 12%; Point of Care revenue fell 27% on a softer respiratory season
- Q3 GAAP net loss $54 million ($0.78 per share); adjusted diluted EPS $0.31
- 2026 guidance: revenue $2.52 to $2.54 billion; adjusted EBITDA $540 to $545 million; adjusted EPS $0.65 to $0.70 (previously $0.65 to $0.90)
- Effective November 9, 2026, Chief Operations Officer Phil McLellan's role is eliminated; Jonathan Siegrist and Bryan Hanson named heads of the two new businesses
Read the filing on SEC.gov ↗
Sep 23, 4:41 PM ET
QuidelOrtho entered into Amendment No. 1 to its credit agreement dated August 21, 2025, with Bank of America as administrative agent. The amendment resets the maximum leverage and minimum interest coverage covenant levels through the fiscal quarter ending September 30, 2029, and sets new pricing and commitment fees during that period. The filing describes added restrictions on the financial covenants, so shareholders gain covenant room but face tighter terms in the interim.
- Amendment dated September 23, 2026 to the credit agreement originally dated August 21, 2025
- Maximum Consolidated Leverage Ratio set at 5.50 to 1.00 for quarters through July 2, 2028, stepping down to 4.25 to 1.00 on or after September 30, 2029
- Minimum Consolidated Interest Coverage Ratio set at 2.25 to 1.00, rising to 3.00 to 1.00 on or after September 30, 2029
- Initial Term SOFR margin of 2.50% per annum for the Term Loan A facilities and revolver until the compliance certificate for the quarter ending September 28, 2026 is received; term loan B interest unchanged
Read the filing on SEC.gov ↗
Aug 6, 4:08 PM ET
QuidelOrtho reported second-quarter 2026 total revenue of $631 million, up 3% as reported, and a GAAP net loss of $93 million, narrower than the $255 million loss a year earlier. The company cut its full-year 2026 revenue, adjusted EBITDA and adjusted EPS guidance and withdrew its free cash flow guidance, citing China demand headwinds and a softer global respiratory environment.
- Q2 2026 total revenue $631 million, up 3% as reported and 2% in constant currency; excluding China, up 6%
- GAAP net loss $93 million, or $1.36 per share, versus $255 million prior-year; adjusted diluted EPS $0.13
- Full-year 2026 revenue guidance lowered to $2.52 billion to $2.60 billion from $2.70 billion to $2.75 billion
- Adjusted EBITDA guidance lowered to $540 million to $560 million from $615 million to $630 million; free cash flow guidance withdrawn (previously $100 million to $120 million)
Read the filing on SEC.gov ↗
Jun 23, 4:04 PM ET
QuidelOrtho appointed Micah Young, former CFO of Masimo, as Chief Financial Officer effective July 6, 2026, succeeding Joseph Busky, who is retiring. Busky will stay in a transition role and then serve as a special advisor to the CEO for up to 24 months. The filing discloses Young's pay package, including a $750,000 base salary and a $6,500,000 inducement RSU grant, which shareholders may track in future proxy and 10-K disclosures.
- Micah Young, 48, becomes CFO effective July 6, 2026, after serving as CFO of Masimo from October 2017 until Masimo's acquisition by Danaher in June 2026
- Young's offer letter sets a $750,000 base salary, a 100% target bonus, a $500,000 cash sign-on bonus and $6,500,000 in inducement RSUs vesting over three years
- Joseph Busky, who announced his retirement in February 2026, will be paid a $340,000 annual base salary for six months after the effective date, then $100,000 as a special advisor for up to 24 months
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.